DGAP-News: STRATEC Biomedical AG / Key word(s): Dividend
STRATEC's Annual General Meeting resolves on dividend increase
06.06.2013 / 19:18
---------------------------------------------------------------------
STRATEC's Annual General Meeting resolves on dividend increase
Birkenfeld, June 6, 2013
At today's Annual General Meeting of STRATEC Biomedical AG (Frankfurt: SBS;
Prime Standard, TecDAX), all items on the meeting's agenda requiring a vote
were approved.
The dividend increase endorsed at the Annual General Meeting represents the
tenth successive rise that STRATEC has distributed to shareholders since
the company started making dividend payments.
For the 2012 financial year, STRATEC will distribute a dividend of EUR 0.56
per share (previous year: EUR 0.55) to its shareholders, corresponding to a
total distribution of EUR 6.6 million. The dividend will be distributed to
shareholders via their custodian banks as of June 10, 2013.
STRATEC's management supported a shareholder motion proposed during the
Annual General Meeting to increase the dividend to EUR 0.56. The proposed
resolution by management initially envisioned a dividend distribution of
EUR 0.50.
At the beginning of his speech at the Annual General Meeting, Marcus
Wolfinger, Chairman of the Board of Management, stated, 'In light of
current information, and due to the improved overall situation since our
initial proposal, we fully support today's motion to increase the dividend
as it enables STRATEC to continue its series of ever-larger dividend
payouts, which so far stands at ten in succession.'
The Annual General Meeting also saw the approval of the Board of
Management's compensation system plus the new compensation structures for
members of the Supervisory Board. Resolutions were also approved regarding
a new stock option program and a corporate contract.
Further information on STRATEC's Annual General Meeting is available at
www.stratec.com > Investor Relations > Annual General Meeting.
About STRATEC
STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully
automated analyzer systems for its partners in the fields of clinical
diagnostics and biotechnology. These partners market such systems, in
general together with their own reagents, as system solutions to
laboratories, blood banks and research institutes around the world. The
company develops its products on the basis of its own patented
technologies.
Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard
segment of the Frankfurt Stock Exchange and are listed in the TecDAX select
index of the German Stock Exchange.
Further information can be obtained from:
STRATEC Biomedical AG
André Loy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999
ir@stratec.com
www.stratec.com
End of Corporate News
---------------------------------------------------------------------
06.06.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: STRATEC Biomedical AG
Gewerbestr. 37
75217 Birkenfeld
Germany
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info@stratec.com
Internet: www.stratec.com
ISIN: DE0007289001
WKN: 728900
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
215331 06.06.2013
DGAP-News: STRATEC's Annual General Meeting resolves on dividend increase
| Source: EQS Group AG